Patients with primary immunodeficiencies are able to respond to COVID-19 vaccine. Anti-SARS-CoV-2 vaccines show significant efficacy in protecting against severe COVID-19 and can potentially limit viral spread. However, their ability to induce a significant immune response in patients with inborn errors of immunity (IEI) is still being evaluated..